ArticleJournal of nanobiotechnology2026
A multifunctional injectable nanocomposite hydrogel for precision keloid therapy via ECM remodeling and local pruritus relief.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Keloids are refractory fibroproliferative disorders. Their treatment faces multiple clinical challenges, including the coexistence of multiple pathological mechanisms, low drug bioavailability, and keloid-related pruritus. This study developed an UV-responsive cross-linked hydrogel (FZRL) using lipoic acid-grafted chitosan (LACS) as the matrix. The hydrogel encapsulates ZIF-8 nanoparticles loaded with 5-fluorouracil (5Fu, denoted as 5Fu@ZIF-8) and the local anesthetic ropivacaine. Before injection, the hydrogel exists as a liquid precursor. It can be precisely delivered to the area around keloids. Under mild UV irradiation, it rapidly cross-links into a stable hydrogel. This enables long-term local retention of 5Fu and ropivacaine, preventing premature drug leakage. In the weakly acidic microenvironment of keloids, FZRL hydrogel degrades specifically and releases 5Fu and ropivacaine on demand. A nude mouse keloid model with subcutaneous inoculation of human keloid fibroblasts (KFs) showed that FZRL hydrogel regulates the TGF-β/Smad pathway. It inhibits KFs proliferation and abnormal angiogenesis, modifies the extracellular matrix structure, and remodels the keloid microenvironment. After treatment, the average keloid volume was reduced by 54.7 ± 12.1%. At the same time, it significantly relieved itching-related scratching and irritable behaviors. In conclusion, FZRL hydrogel has dual delivery properties, including UV-responsive gelation and acid-responsive drug release. It synergistically achieves multi-target anti-keloid effects, as well as pruritus relief and analgesia. It provides a new minimally invasive treatment strategy for refractory keloids and has potential clinical translation value.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.